참고문헌
- Baldo P, Cecco S, Giacomin E, et al (2008). mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets, 8, 647-65. https://doi.org/10.2174/156800908786733513
- Bijnsdorp IV, Peters GJ (2011). Deoxyribose protects against rapamycin-induced cytotoxicity in colorectal cancer cells in vitro. Nucleosides Nucleotides Nucleic Acids, 30, 1197-202. https://doi.org/10.1080/15257770.2011.602657
- Bjornsti MA, Houghton PJ (2004). The TOR pathway: a target for cancer therapy. Nat Rev Cancer, 4, 335-48. https://doi.org/10.1038/nrc1362
- Bruneau S, Nakayama H, Woda CB, Flynn EA, Briscoe DM (2013). DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. Blood, 122, 1833-42. https://doi.org/10.1182/blood-2013-03-488486
- Cai Z, Ke J, He X, et al (2014). Significance of mTOR Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer. Ann Surg Oncol, 21, 179-88. https://doi.org/10.1245/s10434-013-3146-8
- Edge, SB, Compton CC (2010). The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17, 1471-4. https://doi.org/10.1245/s10434-010-0985-4
- Fasolo A, Sessa C (2012). Targeting mTOR pathways in human malignancies. Curr Pharm Des, 18, 2766-77. https://doi.org/10.2174/138161212800626210
- Finn RS (2012). Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition. Liver Cancer, 1, 247-56. https://doi.org/10.1159/000343839
- Friedrichs K, Gluba S, Eidtmann H, Jonat W (1993). Overexpression of p53 and prognosis in breast cancer. Cancer, 72, 3641-7. https://doi.org/10.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-8
- Guertin DA, Sabatini DM (2007). Defining the role of mTOR in cancer. Cancer Cell, 12, 9-22. https://doi.org/10.1016/j.ccr.2007.05.008
- Hay N, Sonenberg N (2004). Upstream and downstream of mTOR. Genes Dev, 18, 1926-45. https://doi.org/10.1101/gad.1212704
- Huang GL, Guo HQ, Yang F, et al (2012).Activating transcription factor 1 is a prognostic marker of colorectal cancer. Asian Pac J Cancer Prev, 13, 1053-7. https://doi.org/10.7314/APJCP.2012.13.3.1053
- Huh JW, Kim HR, Kim YJ, et al (2009). Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int, 59, 241-6. https://doi.org/10.1111/j.1440-1827.2009.02357.x
- Iwaya T, Yokobori T, Nishida N, et al (2012). Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis, 33, 2391-7. https://doi.org/10.1093/carcin/bgs288
- Jacobs BL, Goodman CA, Hornberger TA (2013). The mechanical activation of mTOR signaling: an emerging role for late endosome/lysosomal targeting. J Muscle Res Cell Motil, [Epub ahead of print].
- Kunimura T, Yoshida T, Suqiyama T, Morohoshi T (2009). The Relationships Between Loss of Standard CD44 Expression and Lymph Node, Liver Metastasis in T3 Colorectal Carcinoma. J Gastrointest Cancer, 40, 115-8. https://doi.org/10.1007/s12029-009-9100-0
- Li ZT, Zhang L, Gao XZ, Jiang XH, Sun LQ (2013). Expression and significance of the Wip1 proto-oncogene in colorectal cancer. Asian Pac J Cancer Prev, 14, 1975-9. https://doi.org/10.7314/APJCP.2013.14.3.1975
- Lyzogubov V, Khozhaenko Y, Usenko V, et al (2005). Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer. Exp Oncol, 27, 141-4.
- Martelli AM, Evangelisti C, Follo MY, et al (2011). Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr Med Chem, 18, 2715-26. https://doi.org/10.2174/092986711796011201
- Meng ZX, Li S, Wang L, et al (2013). Baf60c drives glycolytic metabolism in the muscle and improves systemic glucose homeostasis through Deptor-mediated Akt activation. Nat Med, 19, 640-5. https://doi.org/10.1038/nm.3144
- Migliardi G, Sassi F, Torti D, Trusolino L, Bertotti A (2012). Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res, 18, 2515-25. https://doi.org/10.1158/1078-0432.CCR-11-2683
- Mueller S, Phillips J, Onar-Thomas A, et al (2012). PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol, 14, 1146-52. https://doi.org/10.1093/neuonc/nos140
- Nelson LD, Bender C, Mannsperger H, et al (2012). Triplex DNA-binding proteins are associated with clinical outcomes revealed by proteomic measurements in patients with colorectal cancer. Mol Cancer.
- Ostendorff HP, Awad A, Braunschweiqer KI, et al (2013). Multiplexed veracode bead-based serological immunoassay for colorectal cancer. J Immunol Methods, 400-401, 58-69. https://doi.org/10.1016/j.jim.2013.09.013
- Pandurangan AK (2013). Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev, 14, 2201-5. https://doi.org/10.7314/APJCP.2013.14.4.2201
- Peterson TR, Laplante M, Thoreen CC, et al (2009). DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell, 137, 873-86. https://doi.org/10.1016/j.cell.2009.03.046
- Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, 1098-101. https://doi.org/10.1126/science.1106148
- Sarkar S (2013). Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. Biochem Soc Trans, 41, 1103-30. https://doi.org/10.1042/BST20130134
- Sisik A, Kaya M, Bas G, Basak F, Alimoglu O (2013). CEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients. Asian Pac J Cancer Prev, 14, 4289-94. https://doi.org/10.7314/APJCP.2013.14.7.4289
- Sun YX, Mao X, Xie L, et al (2013). Differential Activation of mTOR Complex 1 Signaling in Human Brain with Mild to Severe Alzheimer's Disease. J Alzheimers Dis, 38, 437-44.
- Wang D, Chen J, Guo F, et al (2011). Clinical significance of mTOR and p-mTOR protein expression in human colorectal carcinomas. Asian Pac J Cancer Prev, 12, 2581-4.
- Wang Z, Zhong J, Inuzuka H, et al (2012). An evolving role for DEPTOR in tumor development and progression. Neoplasia, 14, 368-75. https://doi.org/10.1593/neo.12542
- Yang YF, Zhang XY, Yang M, et al (2014). Prognostic role of nucleophosmin in colorectal carcinomas. Asian Pac J Cancer Prev, 15, 2021-6. https://doi.org/10.7314/APJCP.2014.15.5.2021
- Ye C, Kiriyama K, Mistuoka C, et al (1995). Expression of E-selectin on endothelial cells of small veins in human colorectal cancer. Int J Cancer, 61, 455-60. https://doi.org/10.1002/ijc.2910610404
- Zhang HR, Chen JM, Zeng ZY, Que WZ (2013). Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity. J Int Med Res, 41, 584-95. https://doi.org/10.1177/0300060513480920
- Zhao GT, Yang LJ, Li XX, Cui HL, Guo R (2013). Expression of the proto-oncogene Pokemon in colorectal cancer--inhibitory effects of ansiRNA. Asian Pac J Cancer Prev, 14, 4999-5005. https://doi.org/10.7314/APJCP.2013.14.9.4999
- Zhao Y, Xiong X, Sun Y (2011). DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell, 44, 304-16. https://doi.org/10.1016/j.molcel.2011.08.029
피인용 문헌
- Cul1 promotes melanoma cell proliferation by promoting DEPTOR degradation and enhancing cap-dependent translation vol.35, pp.2, 2015, https://doi.org/10.3892/or.2015.4442
- Identification of key genes in colorectal cancer using random walk with restart vol.15, pp.2, 2017, https://doi.org/10.3892/mmr.2016.6058
- Deptor: not only a mTOR inhibitor vol.36, pp.1, 2017, https://doi.org/10.1186/s13046-016-0484-y
- Akt2 causes TGFβ-induced deptor downregulation facilitating mTOR to drive podocyte hypertrophy and matrix protein expression vol.13, pp.11, 2018, https://doi.org/10.1371/journal.pone.0207285
- CASTOR1 suppresses the progression of lung adenocarcinoma and predicts poor prognosis vol.119, pp.12, 2018, https://doi.org/10.1002/jcb.27360